Analyst consensus rating
AgomAb Therapeutics Analyst Rating: Strong Buy
AGMB is rated Strong Buy by 6 analysts with a $37.67 target. As of 2026-09-01.
Direct answer
AgomAb Therapeutics's consensus rating is Strong Buy.
6 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $37.67.
Forecast evidence checked September 1, 2026.
Get free AgomAb Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $13.17
- Average price target
- $37.67
- High price target
- $60.00
- Low price target
- $28.00
- Low target gap
- +112.6%
- Target upside
- +186%
- High target gap
- +355.6%
- Target range width
- 243%
- Consensus rating
- Strong Buy
- Analysts
- 6
- Evidence date
- September 1, 2026
- Valid through
- September 8, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for AgomAb Therapeutics?
AgomAb Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $37.67.
How far are AgomAb Therapeutics's low and high targets from the recorded price?
The low target implies +112.6%, while the high target implies +355.6%.
How many analysts are included in AgomAb Therapeutics's consensus?
The verified consensus includes 6 analysts.
How is AgomAb Therapeutics's target upside or downside calculated?
The average target of $37.67 is divided by the recorded price of $13.17, then one is subtracted to produce +186%. This does not guarantee a future return.
When was AgomAb Therapeutics's analyst forecast verified?
The data was verified on 2026-09-01. The dataset is valid through 2026-09-08.